End-of-Life Choices (Voluntary Assisted Dying) Act 2021

Why it matters (official purpose-claims and how they work mechanically)

• The Act states its objectives as: (a) providing eligible people with an effective process to exercise their choice to reduce suffering by ending their lives legally; (b) protecting people from having their lives ended unwittingly or unwillingly; and (c) providing legal protection to people who assist or do not assist (s3). Mechanically, those objectives are implemented by: strict eligibility rules and definitions (ss6–14); multiple sequential checks (first, second and final requests; PMP/CMP/AHP determinations; Commission authorisations) with specified timeframes and written records (Parts 5–13); criminal penalties for inducement or falsification (Part 18); and statutory protections for good‑faith compliance (s135).

Who is affected and who decides

• Affected people: adults (18+) who meet residency (s11), medical and capacity criteria (ss6,10,12–14). Family, carers and appointed contact persons play defined roles (ss85,82(4),15). Practitioners and pharmacists are affected by duties to assess, refer, notify and keep records (many sections: e.g. ss17,23,24,25,43,71,73–77,119). The State is affected through establishing and resourcing the Commission and administrative arrangements (s110, s147).

• Decision‑makers: PMPs, CMPs and AHPs make the clinical eligibility and capacity decisions (ss26,33,47,78–81). The Commission issues drug authorisations, approves training, maintains lists of willing providers, may investigate compliance and can revoke authorisations (ss67,69,116–117,114,122). The Commission and courts provide review and appeal routes (Part 15; ss95–105).

Who pays and administrative responsibilities

• The Act assigns administration to the Minister for Health and the Department until other arrangements are made (s147). The Commission members receive remuneration fixed by the Governor (s110(4)). The Act places record‑keeping, notification and reporting duties on PMPs, CMPs, AHPs and pharmacists, and requires them to notify the Commission at specific points; failure can attract fines (e.g. ss29,36,50,71(4),119,130). The Act does not prescribe user fees or private charging rules for services; it permits practitioners to receive "reasonable fees" but bars parties who would directly benefit from a person’s death from acting in certain roles (see definitions and s9(f)).

Key incentives, trade‑offs and costs (mechanisms, not judgements)

• Multiple checks impose compliance costs on clinicians and the state. The stepwise model (first/second/final requests; PMP → CMP → commission authorisation → prescription → supply → administration or private self‑administration) creates administrative workload and fixed timeframes (e.g. 48 hours, 7 days) for decisions and notifications (see Part 5–13). Those requirements increase clinician time per case and require Commission capacity to process authorisations and maintain lists (ss19,23,24,66–71,119).

• The Act balances clinician choice and system access. Clinicians may conscientiously refuse to accept requests, refuse referrals, refuse to be appointed as AHPs, and pharmacists may refuse supply (ss20,40,64,71(3)). At the same time the Commission must maintain lists of willing practitioners and can appoint an AHP on request by a PMP (ss114(1)(c)–(f), 62). This structure creates an administrative pathway intended to secure access where an individual’s PMP or local practitioners decline to participate, while preserving practitioners’ ability to opt out.

• Regulatory discretion is concentrated in the Commission. The Commission approves training (s117), determines permitted VAD substances (s116), issues and revokes authorisations (ss67–69), keeps lists of willing providers (s114), and can investigate and require information (ss122–123). Those powers allow central oversight but also delegate significant operational judgment to an administrative body.

• Supply chain and clinical safety obligations are specified and intersect with other laws. Pharmacists must consult patients before supply, label packaging, record and notify the Commission of supply, and may refuse supply (s71). The Act overrides inconsistent provisions in the Misuse of Drugs Act to the extent necessary (s141(1)), but continues to require compliance with the Poisons Act for prescription, sale, storage and destruction unless expressly prescribed otherwise (s141(2)–(3)). These cross‑law interactions create implementation work for pharmacies, clinicians and regulators.

Implementation risks and compliance burdens

• Timely appointments, training approval and Commission resourcing will be required to meet the time limits and reporting duties embedded in the Act (example timeframes: accept/refuse first request 48 hours s19; PMP to notify within 7 days s23; AHP final determination 48 hours before final permission s78; many 7‑day or 48‑hour notification windows appear throughout Parts 5–14).

• Record and disclosure obligations are extensive: practitioners must place determinations on medical records, provide copies to the Commission, and to other treating practitioners on request (e.g. ss29,36,50,73–77,119). Notices and returns of unused substances are time‑bound (ss76–77,92).

• Criminal sanctions attach to inducement, falsification and related misconduct (ss124–129,127–128). The Act also provides statutory protection for good‑faith action (s135), and protection from professional sanction for persons complying in good faith (s135(2)–(3)).

Effects on private choice, markets and independent providers

• Private clinicians and pharmacists retain the freedom to refuse involvement for conscience or other reasons (ss20,40,64,71(3)). They may also join Commission lists to offer services (s114(1)(c)–(f)). That creates a mixed landscape where individuals’ access depends on local willingness and the Commission’s ability to publish and maintain lists of willing providers.

• The Act does not regulate pricing or require providers to offer services for free. It allows providers to receive reasonable fees for services (s9(f) reference to reasonable fees). Independent practitioners and pharmacies therefore remain able to contract and charge, subject to professional regulation and the Act’s duties.

Checks, review and transparency

• The Act builds in review and appeal mechanisms. Eligible applicants can ask the Commission to review residency, capacity or voluntariness determinations (Part 15, ss95–103). Commission decisions are subject to appeal to the Supreme Court on questions of law (s105).

Summary of trade‑offs identified in the Act (mechanical description)

• Access vs procedural safeguards: multiple independent clinical checks and Commission authorisations aim to reduce wrongful deaths but increase the number of procedural steps, timeframes and reporting obligations for clinicians and the Commission (see Parts 5–9, 12, 17).

• Practitioner autonomy vs system availability: clinicians and pharmacists may opt out; the Commission must maintain lists and may appoint alternate AHPs to keep access available (ss114,62,64).

• Centralised oversight vs local variation: the Commission centralises authorisations, approvals and monitoring (ss114,116–117,122), which concentrates discretion and requires central resourcing to manage local demand.

Key statutory references for quick navigation

• Eligibility and definitions: ss5–14
• Request, acceptance and PMP/CMP pathway: Parts 5–9 (ss18–50)
• Final permission, private self‑administration and administration: Parts 10–14 (ss53–93)
• Commission powers and administration: Part 17 (ss110–120,116–117)
• Offences and protections: Parts 18–19 (ss124–136)
• Interactions with other Acts and administrative assignment: ss141,147

This summary describes the legal structure, duties, decision points, reporting burdens, and enforcement architecture set out in the Act and notes where discretionary choices or cross‑law interactions create implementation demands (specific provisions cited above).